FOR RESEARCH USE ONLY
Constituent evidence onlyRecovery research

BPC-157 / TB-500

Pre-mixed BPC-157 and TB500 blend researched for synergistic soft-tissue and connective recovery.

01Connective tissue02Cytoprotection03Cell migration
Molecular signature / bpc-tb500-blend
Structural identity

Equimass combination of two distinct repair-pathway compounds

Also known as

BPC-157 + TB-500 combination · Wolverine research blend

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

A combined vial of BPC-157 and TB500 (Thymosin Beta-4 fragment) at a 1:1 ratio. The two peptides are frequently stacked in research protocols to target overlapping but distinct repair pathways — BPC-157 driving local cytoprotection and angiogenesis, TB500 driving systemic cell migration and actin remodelling. The blend simplifies dosing logistics for combined recovery work.

The research question

The combination pairs a cytoprotective research target with an actin-regulation target. It should be analysed as two exposures in one preparation: total mass, mass per constituent and the absence of direct combination evidence all matter.

Section 02

Mechanism & research themes

BPC-157 acts via the NO system, VEGF/EGF growth-factor signalling and FAK-paxillin pathway activation. TB500 sequesters G-actin monomers to drive cell migration, angiogenesis and progenitor recruitment. Together they target both the local injury site (BPC-157) and systemic repair cell mobilisation (TB500).

01

Dual-pathway acceleration of tendon, ligament and muscle recovery

02

Combined local cytoprotection and systemic repair-cell recruitment

03

Enhanced angiogenesis and microvascular remodelling at injury sites

04

Anti-inflammatory effects across NF-κB, TNF-α and IL-1β axes

05

Single-injection convenience for stacked recovery protocols

06

Frequently cited synergy in connective-tissue and post-surgical research

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Constituent evidence only

There is no robust controlled literature for the combined preparation. Any rationale comes from separate BPC-157 and TB-500 studies, which are themselves largely preclinical.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 250–500mcg of each peptide once daily, or split into a morning/evening dose, subcutaneously near the site of interest. Cycles typically run 4–8 weeks on / 4 weeks off.

Reported persistence

BPC-157: approximately 4 hours. TB500: approximately 30–80 minutes plasma, with multi-day functional depot effect post SC/IM.

Calculator starting point

0.5 mg per reference dose

4 doses per week · 6-week cycle

3 mL default reconstitution volume

Equal-parts BPC-157 + TB500 blend. Commonly dosed 4–7×/week over 4–8 week cycles.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate BPC-157 / TB-500
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 20mg blend vial (10mg BPC-157 + 10mg TB500) with 3mL bacteriostatic water, or a 30mg blend vial (15mg BPC-157 + 15mg TB500) with 3mL BW for a 10mg/mL combined concentration (5mg/mL of each). Swirl gently — do not shake.

Storage reference

Lyophilised: 2–8°C, stable up to 24 months; avoid freeze-thaw cycles. Reconstituted: 2–8°C, protect from light, use within 30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Inherits the angiogenesis-related precaution of both parent peptides — avoid with active malignancy.

L2

Transient post-injection 'head rush' or mild fatigue may occur from the TB500 component.

L3

Direct combination-blend human data is limited; outcomes are extrapolated from single-peptide research.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only